On Apr. 13, 2021, Moderna announced that new results from a preclinical study of the Companyﾒs COVID-19 variant-specific vaccine candidates showed that the Companyﾒs variant-specific booster vaccine candidates (mRNA-1273.351 and mRNA-1273.211) increase neutralizing titers against SARS-CoV-2 variants of concern. To date, the Company had delivered approximately 132 million doses of the Moderna COVID-19 Vaccine globally.